Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Sell
37
TCBP Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
-22.96%
Day range:
$0.61 - $0.67
52-week range:
$0.44 - $41.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.16x
Volume:
758.8K
Avg. volume:
2.4M
1-year change:
-96.77%
Market cap:
$5.5M
Revenue:
--
EPS (TTM):
-$70.64
Analysts' Opinion
-
Consensus RatingTC BioPharm (Holdings) PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, TC BioPharm (Holdings) PLC has an estimated upside of 349.17% from its current price of $0.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.67.
Fair Value
-
According to the consensus of 0 analysts, TC BioPharm (Holdings) PLC has 349.17% upside to fair value with a price target of -- per share.
TCBP vs. S&P 500
-
Over the past 5 trading days, TC BioPharm (Holdings) PLC has overperformed the S&P 500 by 28.82% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
TC BioPharm (Holdings) PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TC BioPharm (Holdings) PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter TC BioPharm (Holdings) PLC reported revenues of --.
Earnings Growth
-
TC BioPharm (Holdings) PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter TC BioPharm (Holdings) PLC reported earnings per share of -$5.07.
Enterprise value:
4.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Income Statement | ||||||
| Revenue | $2.6M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$15.7M | -$16.5M | -$4.5M | -$2.6M | |
| EBITDA | -- | -$20.4M | -$15.8M | -$4.3M | -$2.4M | |
| Diluted EPS | -- | -$7,683.21 | -$70.64 | $37.69 | -$5.07 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $11.9M | $6.2M | $5M | |
| Total Assets | -- | -- | $16.5M | $10.4M | $8.7M | |
| Current Liabilities | -- | -- | $10.6M | $5.8M | $4.5M | |
| Total Liabilities | -- | -- | $15.2M | $7.8M | $6.2M | |
| Total Equity | -- | -- | $1.2M | $2.5M | $2.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13.9M | -$15.7M | -$15.1M | -$5M | -$3.4M | |
| Cash From Investing | -- | -- | -$316.4K | -$94.9K | -$37.9K | |
| Cash From Financing | -- | -- | $9.9M | $421K | $3.5M | |
| Free Cash Flow | -- | -$15.8M | -$15.4M | -$5.1M | -$3.5M | |
TCBP
Sector
Market Cap
$5.5M
$44.6M
Price % of 52-Week High
1.61%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-96.77%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.59
200-day SMA
Sell
Level
$7.76
Bollinger Bands (100)
Sell
Level
1.06 - 5.76
Chaikin Money Flow
Sell
Level
-141.6M
20-day SMA
Buy
Level
$0.61
Relative Strength Index (RSI14)
Sell
Level
37.99
ADX Line
Neutral
Level
Williams %R
Neutral
Level
-41.2668
50-day SMA
Sell
Level
$1.47
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
172.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Stock Forecast FAQ
In the current month, TCBP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TCBP average analyst price target in the past 3 months is --.
-
Where Will TC BioPharm (Holdings) PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that TC BioPharm (Holdings) PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About TC BioPharm (Holdings) PLC?
Analysts are divided on their view about TC BioPharm (Holdings) PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TC BioPharm (Holdings) PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is TC BioPharm (Holdings) PLC's Price Target?
The price target for TC BioPharm (Holdings) PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TCBP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TC BioPharm (Holdings) PLC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TCBP?
You can purchase shares of TC BioPharm (Holdings) PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TC BioPharm (Holdings) PLC shares.
-
What Is The TC BioPharm (Holdings) PLC Share Price Today?
TC BioPharm (Holdings) PLC was last trading at $0.66 per share. This represents the most recent stock quote for TC BioPharm (Holdings) PLC. Yesterday, TC BioPharm (Holdings) PLC closed at $0.67 per share.
-
How To Buy TC BioPharm (Holdings) PLC Stock Online?
In order to purchase TC BioPharm (Holdings) PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
